Skip to content

Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy

Improving Food Pleasure and Intake of Oncology Patients Receiving Chemotherapy

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04495387
Enrollment
100
Registered
2020-07-31
Start date
2021-07-31
Completion date
2022-12-31
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Chemotherapeutic Toxicity, Colon Cancer

Brief summary

The global cancer burden is estimated to have risen to 18.1 million new cases in 2018 (WHO), with a trend of ongoing growth. This very frequent illness exerts tremendous physical, emotional and financial strain on individuals, families, communities and health systems. Malnutrition (under- or over-nutrition) is highly prevalent in cancer patients receiving chemotherapy and is an important predictor of morbidity, mortality, treatment response and toxicity. Alterations in taste and smell are frequently reported as side effect of chemotherapy and may contribute strongly to malnutrition and to a worsen quality of life and wellbeing social, emotional, and role functioning. There are evidences that chemotherapy influences food liking and appetite with implications for food behaviours, including food enjoyment, food preference and dietary intake. A linkage between alterations in taste and /or smell and food behaviours has been reported by some studies but not all, suggesting that there is a need for more research using common standardised methodologies and larger sample size to gain a further insight into this topic.

Interventions

DRUGChemotherapy

standard adjuvat chemotherapy for reast and colo cancer

Sponsors

University of Florence
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* pathological diagnosis of colorectal or breast cacer * indication to adjuvant chemotherapy for colon cancer according local guide lines * indication to (neo)-adjuvant chemotherapy for reast cancer according local guide lines * possiility to sign an informed consent

Exclusion criteria

* patients aged \<18 years * patients aged \>80 years

Design outcomes

Primary

MeasureTime frameDescription
change of taste chemotherapy-related alterationsthe variables will be measured at four time points: before chemotherapy (T0), after 4 cycles (T1, each cycle is 21 days), at the end of chemotherapy (T2, 6 months from T0) and three months after the conclusion of the therapy (T3, 9 months from T0)To better understand alteration of taste/smell and food behaviours by the self-report responses, using an adapted version of a questionnaire set up to measure taste changes due to COVID-19

Secondary

MeasureTime frameDescription
Emotions elicited by foodsthe variables will be measured at four time points: before chemotherapy (T0), after 4 cycles (T1, each cycle is 21 days), at the end of chemotherapy (T2, 6 months from T0) and three months after the conclusion of the therapy (T3, 9 months from T0)Emotions elicited by foods will be measured on a selection of foods through an EmoSemio questionnaire, a self-report measure of emotion developed based on preliminary interviews

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026